ARYX (ARYx Therapeutics) Short-Term Debt: $6.83 Mil (As of Sep. 2010)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is ARYx Therapeutics Short-Term Debt?

ARYx Therapeutics ARYX -99.80% Short-Term Debt is $6.83 Mil as of Sep. 2010.

ARYx Therapeutics's Short-Term Debt for the quarter that ended in Sep. 2010 was $6.83 Mil.

ARYx Therapeutics's quarterly Short-Term Debt declined from Mar. 2010 ($4.10 Mil) to Jun. 2010 ($3.34 Mil) but then increased from Jun. 2010 ($3.34 Mil) to Sep. 2010 ($6.83 Mil).

ARYx Therapeutics's annual Short-Term Debt declined from Dec. 2007 ($3.54 Mil) to Dec. 2008 ($3.40 Mil) but then increased from Dec. 2008 ($3.40 Mil) to Dec. 2009 ($4.85 Mil).

ARYx Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

ARYx Therapeutics Short-Term Debt Related Terms

ARYx Therapeutics Short-Term Debt Historical Data

* Premium members only.

The historical data trend for ARYx Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ARYx Therapeutics Short-Term Debt Chart

ARYx Therapeutics Annual Data
Trend Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09
Short-Term Debt
Get a 7-Day Free Trial 2.24 3.20 3.54 3.40 4.85

ARYx Therapeutics Quarterly Data
Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.79 4.85 4.10 3.34 6.83
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $6.83 Mil mean?
ARYx Therapeutics (ARYX) has a Short-Term Debt of $6.83 Mil as of Sep. 2010.
Is ARYx Therapeutics' Short-Term Debt too high?
ARYx Therapeutics' current Short-Term Debt is $6.83 Mil.
How does ARYx Therapeutics' Short-Term Debt compare to YBAO and HPMM?
ARYx Therapeutics' Short-Term Debt of $6.83 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. ARYx Therapeutics's current Short-Term Debt is $6.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ARYx Therapeutics stock overvalued right now?
ARYx Therapeutics (ARYX) has a current Short-Term Debt of $6.83 Mil. The current Short-Term Debt is $6.83 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For ARYx Therapeutics (ARYX), the current Short-Term Debt is $6.83 Mil as of Sep. 2010. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ARYx Therapeutics Business Description

Address 6300 Dumbarton Circle, Fremont, CA, USA, 94555
ARYx Therapeutics Inc is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates designed to eliminate known safety issues associated with well-established, commercially successful drugs.